We serve Chemical Name:2-chloro-6-fluoro-3-methylbenzyl alcohol CAS:261762-83-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-chloro-6-fluoro-3-methylbenzyl alcohol
CAS.NO:261762-83-8
Synonyms:2-Chloro-6-fluoro-3-methylbenzyl alcohol;MFCD01631362;2-chloro-3-methyl-6-fluorobenzyl alcohol;(2-chloro-6-fluoro-3-methylphenyl)methan-1-ol;(2-chloro-6-fluoro-3-methyl-phenyl)-methanol
Molecular Formula:C8H8ClFO
Molecular Weight:174.60000
HS Code:2906299090
Physical and Chemical Properties:
Melting point:56-58°C
Boiling point:245.7ºC at 760mmHg
Density:1.286g/cm3
Index of Refraction:1.537
PSA:20.23000
Exact Mass:174.02500
LogP:2.27980
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Chloro-6-fluoro-3-methylbenzyl alcohol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2-chloro-6-fluoro-3-methyl-phenyl)-methanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Chloro-6-fluoro-3-methylbenzyl alcohol Use and application,(2-chloro-6-fluoro-3-methyl-phenyl)-methanol technical grade,usp/ep/jp grade.
Related News: In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China. 2-chloro-6-fluoro-3-methylbenzyl alcohol manufacturer Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 2-chloro-6-fluoro-3-methylbenzyl alcohol supplier What’s the background? 2-chloro-6-fluoro-3-methylbenzyl alcohol vendor Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 2-chloro-6-fluoro-3-methylbenzyl alcohol factory What’s the background?
